CASE REPORT

Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis

Naohiro Oda, Masahiro Tabata, Masatoshi Uno, Yuzo Umeda, Hironari Kato, Toshio Kubo, SatoruSenoo, Takahito Yagi, Toshiyoshi Fujiwara, Yoshinobu Maeda and Katsuyuki Kiura

Abstract:
Mucinous cystic neoplasm (MCN) of the pancreas is a rare cystic tumor occurring in the pancreatic body and tail in young to middle-aged women that is pathologically characterized by an ovarian-like stroma. Chemotherapy for recurrent/advanced pancreatic MCN has been based on chemotherapy regimens for pancreatic ductal adenocarcinoma, but the prognosis is poor. We herein report a 37-year-old woman with pancreatic mucinous cystadenocarcinoma with liver metastasis that responded dramatically to carboplatin plus paclitaxel therapy (CBDCA + PTX). CBDCA + PTX may be a treatment option for recurrent/advanced pancreatic MCN with an ovarian-like stroma.

Key words: pancreas, mucinous cystadenocarcinoma, carboplatin, paclitaxel

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.6730-20)

Introduction
Mucinous cystic neoplasm (MCN) of the pancreas is a rare cystic tumor occurring exclusively in the pancreatic body and tail of young to middle-aged women. MCN is pathologically characterized by an ovarian-like stroma (1). Surgical resection is recommended after the diagnosis of MCN because of the risk of malignancy (2, 3). Chemotherapy for recurrent/advanced pancreatic MCN has been based on chemotherapy regimens for pancreatic ductal adenocarcinoma, but the prognosis is poor (4, 5).

We herein report a 37-year-old woman with pancreatic mucinous cystadenocarcinoma (MCC) with liver metastasis that responded dramatically to carboplatin plus paclitaxel therapy (CBDCA + PTX).

Case Report
A 37-year-old woman was examined at another hospital with a complaint of a high fever. Abdominal ultrasonography showed a liver mass, and the patient was treated with antibacterial agents for a suspected liver abscess. However, the patient’s condition did not improve, so she was referred to our hospital. The patient did not have any personal or family history of cancer. Laboratory tests revealed leukocytes, 36,430/μL (neutrophil, 89.5%; lymphocyte, 0.5%; monocyte, 5.5%; eosinophil, 0.5%; basophil, 0.5%; metamyelocyte, 3.0%; myelocyte, 0.5%; erythroblast, 1.0%); hemoglobin, 6.3 g/dL; platelets, 579,000/μL; prothrombin...
time, 21.7 seconds; activated partial thromboplastin time, 31.2 seconds; fibrinogen, 1,257 mg/dL; fibrinogen/fibrin degradation products, 16.9 μg/mL; D-dimer, 8.7 μg/mL; HbA1c, 6.7%; serum aspartate aminotransferase, 63 U/L; alanine aminotransferase, 27 U/L; total bilirubin, 1.11 mg/dL; alkaline phosphatase, 1,031 U/L; lactate dehydrogenase, 443 U/L; amylase, 17 U/L; albumin 1.6 g/dL; C-reactive protein, 16.17 mg/dL; free triiodothyronine, 1.04 pg/mL; free thyroxine, 0.92 ng/dL; thyroid-stimulating hormone, 5.27 μIU/mL; carcinoembryonic antigen (CEA), 94.09 ng/mL; carbohydrate antigen (CA)19-9, 5.7 U/mL; CA125, 13,041 U/mL; and α-fetoprotein, 1.7 ng/mL. Hepatitis B and C were negative. Abdominal contrast-enhanced computed tomography (CT) showed a large mass with heterogeneous contrast enhancement occupying the right lobe of the liver, an 85-mm cyst with a mural nodule on the tail of the pancreas, para-aortic lymphadenopathies, and a large amount of ascites (Fig. 1A, B). The hepatic inferior vena cava (IVC) was severely compressed by the liver tumor, and thrombosis was found in the left lower extremity. A trans-venous needle biopsy of the liver was performed, and adenocarcinoma with tubular and papillary growths was diagnosed (Fig. 2).

Her general condition worsened with the appearance of jaundice for several days (total bilirubin level increased to 4.37 mg/dL). Pelvic magnetic resonance imaging showed normal ovaries. Treatment with CBDCA + weekly PTX was started for the diagnosis of adenocarcinoma of an unknown primary site. After two courses of CBDCA + weekly PTX, the tumor gradually shrank (Fig. 3A, B) and her performance status (PS) improved from 3 to 1. Anemia due to inflammation and liver dysfunction associated with malignancy also improved after her response to chemotherapy (hemoglobin, 10.3 g/dL and total bilirubin, 0.51 mg/dL). The major grade ≥3 adverse events were grade 3 leukopenia, anemia, and thrombocytopenia and grade 4 neutropenia but not febrile neutropenia (Common Terminology Criteria for Adverse Events version 5.0). The thrombosis in her left lower extremity shrank following the administration of warfarin. Fluorodeoxyglucose-positron emission tomography (FDG-PET/CT after 3 courses of chemotherapy showed significantly reduced tumors in the right lobe of the liver (maximum standardized uptake value: 2.94) (Fig. 3D) and diminished para-aortic lymphadenopathies and ascites. FDG-PET/CT also revealed a high FDG uptake in the right lobe of the thyroid, suggestive of thyroid cancer (maximum standardized uptake value: 7.10). After 10 courses of chemotherapy, the serum CEA and CA125 levels were decreased to 6.3 ng/mL and 20.5 U/mL, respectively (Fig. 5); the liver tumor was reduced from a diameter of 125 to 23 mm; and the maximum response was considered to have been achieved (Fig. 3C); therefore, the patient underwent right hepatectomy with IVC resection and repair using artificial blood vessels, distal pancreatectomy, cholecystectomy, and splenectomy. Tubular and papillary invasive adenocarcinoma was identified from the columnar epithelium of the pancreatic cyst wall, and ovarian-like stroma was noted (Fig. 4A-C). The liver tumor had similar pathological findings (Fig. 4D). Finally, pancreatic MCC with liver metastasis was diagnosed.

After 3 courses of postoperative CBDCA + weekly PTX, the patient underwent right thyroidectomy and D1 lym-
phadectomy for papillary thyroid cancer. After one course of postoperative CBDCA + weekly PTX, the tumor relapsed, with lung metastasis confirmed by a CT-guided needle biopsy. The tumor did not respond to two courses of gemcitabine or six courses of 5-fluorouracil plus oxaliplatin plus irinotecan (FOLFIRINOX), and she ultimately died of respiratory failure due to multiple lung metastases 21 months after CBDCA + weekly PTX was first started.

**Figure 3.** Abdominal computed tomography before chemotherapy (A), after 2 courses of chemotherapy (B), and after 10 courses of chemotherapy (C). Fluorodeoxyglucose-positron emission tomography/computed tomography after 3 courses of chemotherapy (D) showing a significantly shrunken tumor in the right lobe of the liver (maximum standardized uptake value: 2.94).

**Figure 4.** Hematoxylin and Eosin (H&E) staining of the pancreatic tumor specimen showing tubular and papillary adenocarcinoma with stromal invasion from the columnar epithelium of the pancreatic cyst wall (A, B) and ovarian-like stroma (C). H&E staining of the liver tumor specimen showing tubular and papillary adenocarcinoma (D).
Discussion

MCN has a low prevalence of invasive carcinoma (<15% of resected cases), and MCN <4 cm in size without mural nodules tends to be benign (6, 7). Because of the relatively young age of most patients with MCN, the risk of progression to invasive carcinoma, and the common tumor locations of the pancreatic body and tail, surgical resection is recommended for all surgically fit patients (2). In this case, the MCN was large (85 mm in diameter) and had a mural nodule at the initial presentation, so there was a high probability of malignancy. Although the patient had a fairly progressive disease and poor PS, CBDCA + PTX rapidly improved her general condition, resulting in a dramatic therapeutic response. The diagnosis of liver metastasis of pancreatic MCC was ultimately made using surgical biopsies.

The most appropriate chemotherapy for recurrent/advanced pancreatic MCN has not been investigated in clinical trials because of the rarity of the disease. In practice, regimens for pancreatic ductal carcinoma are often used. Bruenetti et al. reported that 12 of 15 patients with pancreatic MCC were treated with chemotherapy including gemcitabine, and the remaining 3 were treated with FOLIRINOX as the first-line therapy (4). Three of the 4 patients with an overall survival greater than 15 months received cisplatin plus gemcitabine as the first-line therapy: 1 had a partial response, and 2 had stable disease (SD). All three patients who received FOLFILINOX as the first-line therapy had SD. The three patients who received gemcitabine plus nab-PTX as the first- or the second-line therapy responded insuffi- ciently to this regimen: one had SD, and two had progressive disease. There have been other case reports of patients with pancreatic MCC who responded well to gemcitabine plus oxaliplatin and were able to undergo surgical resec-

Figure 5. Clinical course. CEA: carcinoembryonic antigen, CA125: carbohydrate antigen 125, CBDCA+PTX: carboplatin plus paclitaxel, GEM: gemcitabine, FOLFIRINOX: folinic acid plus 5-fluorouracil plus oxaliplatin plus irinotecan, MCC: mucinous cystadenocarcinoma, CT: computed tomography

...
for recurrent/advanced pancreatic MCN with an ovarian-like stroma.

The authors state that they have no Conflict of Interest (COI).

References

1. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 23: 410-422, 1999.

2. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17: 738-753, 2017.

3. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67: 789-804, 2018.

4. Brunetti O, Aprile G, Marchetti P, et al. Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis. Pancreas 47: 759-771, 2018.

5. Doulamis IP, Mylonas KS, Kalfountzos CE, Mou D, Haj-Ibrahim H, Nasioudis D. Pancreatic mucinous cystadenocarcinoma: epidemiology and outcomes. Int J Surg 35: 76-82, 2016.

6. Reddy RP, Smyrk TC, Zapiach M, et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol 2: 1026-1031, 2004.

7. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 247: 571-579, 2008.

8. Obayashi K, Ohwada S, Sunose Y, et al. Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous neoplasm of the pancreas. Gan To Kagaku Ryoho 35: 1915-1917, 2008.

9. DiMarco M, Vecchiarelli S, Macchini M, et al. Preoperative gemcitabine and oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma. Case Rep Gastroenterol 6: 530-537, 2012.

10. Pearl ML, Valea F, Chumas J, Chalas E. Primary retroperitoneal mucinous cystadenocarcinoma of low malignant potential: a case report and literature review. Gynecol Oncol 61: 150-152, 1996.

11. Kessler TM, Kessler W, Neuwelder J, Nachbur BH. Treatment of a case of primary retroperitoneal mucinous cystadenocarcinoma: is adjuvant hysterectomy and bilateral salpingo-oophorectomy justified? Am J Obstet Gynecol 187: 227-232, 2002.

12. Ohtsuka T, Nakamura M, Hijjoka S, et al. Prediction of the probability of malignancy in mucinous cystic neoplasm of the pancreas with ovarian-type stroma: a nationwide multicenter study in Japan. Pancreas 49: 181-186, 2020.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/).